Delcath Systems extends melphalan supply agreement through Dec 2028; modifies pricing terms

DELCATH SYSTEMS, INC.

Term extended to December 31, 2028; effective May 1, 2024.
Purchase orders for melphalan HCl must be placed at least 210 days before delivery.
Price per vial modified; annual increases tied to pharmaceutical preparation PPI.
Agreement with Synerx Pharma, LLC and Mylan Teoranta for key drug supply.
Fifth Amendment dated April 22, 2024, ensures long-term supply continuity.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DELCATH SYSTEMS, INC. amended Fifth Amendment with Synerx Pharma, LLC and Mylan Teoranta (effective 2024-04-22).

Action: amendment
Agreement: license
Counterparty: Synerx Pharma, LLC and Mylan Teoranta
Effective: 2024-04-22

Exact text from the filing

On April 22, 2024, Delcath Systems, Inc. (“Delcath”) entered into a Fifth Amendment, effective May 1, 2024 (the “Amendment”), to the License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta, dated October 13, 2010 (as subsequently amended, the “Agreement”), for Delcath’s supply of melphalan hydrochloride (the “Product”).

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-115922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.